#Italy #Kedrion Biopharma #Castelvecchio Pascoli #Immunodeficiencies #IPIC 2025

Kedrion Takes Center Stage at IPIC 2025

Kedrion Biopharma, a prominent player in plasma-derived therapies, recently announced its significant involvement in the International Congress on Primary Immunodeficiencies (IPIC) 2025. This event is set to take place from November 5 to 7, 2025, in Prague, Czech Republic, focusing on the increasing concerns surrounding secondary immunodeficiencies.

During the congress, Kedrion is hosting a satellite symposium titled “Secondary Immunodeficiencies in Hematologic Malignancies: A Growing Area of Interest”, aiming to address one of the pivotal and evolving issues in immunology. The symposium is structured around the insights of leading experts, including Dr. Fabian Peissker, Kedrion’s Medical Affairs Lead, alongside renowned speakers like Hermann Wolf from Sigmund Freud University and Dr. Federica Pulvirenti from Policlinico Umberto I in Rome. They will tackle the challenges and advancements in diagnosing and managing secondary immunodeficiencies (SID) in patients with hematologic malignancies, emphasizing real-world clinical experiences and facilitating interactive Q&A sessions.

The Importance of Addressing Secondary Immunodeficiencies

Secondary immunodeficiencies, particularly among B-cell malignancy patients, pose significant clinical challenges due to their intricate pathogenesis and heightened infection risks. While advancements in cancer therapies have improved survival rates, complications like hypogammaglobulinemia and various infections can severely impact patient outcomes and overall quality of life. Timely diagnosis and appropriate management—including immunoglobulin replacement therapy—are crucial for enhancing patient care and minimizing infection-related complications.

Kedrion’s participation in IPIC 2025 underscores the firm’s commitment to advancing knowledge and fostering collaboration within the medical and scientific community, especially regarding secondary immunodeficiencies. By sponsoring this valuable symposium, Kedrion is demonstrating an increasing dedication to this crucial and dynamic field.

Beyond the symposium, Kedrion enhances its presence at the conference with a booth, three visual presentation sessions, and representatives from around the globe, reaffirming its dedication to innovation in treating immunodeficiencies. The visual presentations, crafted in collaboration with leading experts and patient advocacy groups, will showcase the latest scientific research and its implications. An information corner at the Kedrion booth will provide congress attendees with direct access to medical and scientific experts, creating an invaluable hub of information and discussion.

Insights from Experts

Roberto Crea, Therapeutic Area Lead in Immunology at Kedrion, highlighted the ongoing uncertainties surrounding the complex interactions between primary and secondary immunodeficiencies. He states, “Research is vital to understand better how these conditions interact with each other, aiming for better patient support.” Kedrion is making concerted efforts to broaden understanding in this realm and encourage interaction among specialists involved in managing SID. The priorities include raising awareness of these conditions and defining common principles to identify patient needs while promoting collaboration across all healthcare stakeholders. Achieving success in these endeavors will ultimately enhance patient outcomes and quality of life.

The significance of collaboration was echoed by Martine Pergent, President of the International Patient Organization for Primary Immunodeficiencies (IPOPI). She stressed the importance of leveraging expertise across the spectrum of immunodeficiencies to meet the needs of SID patients, stating, “Primary immunodeficiencies are no longer exclusively defined by infections. They encompass a broader spectrum of conditions with overlapping clinical features.”

Given the challenges at hand, more profound collaboration is essential, particularly with hematologists treating SID, aiming to synergize with those managing primary immunodeficiencies to improve care and long-term quality of life for these patients. Collecting real-world data that accurately reflect their situations and needs will be pivotal.

A Premier Multidisciplinary Gathering

The IPIC is a leading international multidisciplinary congress focusing on primary immunodeficiencies and innate immunity disorders, with a patient-centered approach. The 2025 edition expects to host over 900 participants from more than 70 countries, providing a unique platform for scientific exchange and collaboration.

Kedrion's sponsored symposium is accessible to all IPIC participants, serving as an opportunity to delve into recent developments in secondary immunodeficiencies throughout the congress. Scientific insights and expert opinions will also be available at Kedrion’s booth (#17), where attendees can learn about advancements in immunodeficiency management and connect with leading experts in this imperative field.

For further details on Kedrion, visit www.kedrion.com.